Long-term data from the KEYNOTE-010 trial showed that 35% of over 1,000 patients with non-small cell lung cancer (NSCLC) who had progressed on chemotherapy and were then treated with pembrolizumab remained alive after 3 years. Patients in this study were randomized to receive immunotherapy with pembrolizumab or chemotherapy with docetaxel. Of the 10% of patients who received the complete 35 cycles of pembrolizumab, 3-year overall survival was approximately 99%. Lead investigator Roy Herbst, MD, PhD, of the Department of Medical Oncology at Yale Comprehensive Cancer Center in New Haven, Connecticut called these results “really extraordinary.”

For more details on the published study results, click here.